

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM577161

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Strongbridge Dublin Limited		05/19/2020	Private Limited Company: IRELAND
RECEIVING PARTY DATA			
Name:	Avenue Venture Opportunities Fund, L.P. As Administrative Agent		
Street Address:	11 W. 42nd St. 9th Floor		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10036		
Entity Type:	Limited Partnership: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	5237588	STRONGBRIDGE BIOPHARMA	
Registration Number:	5851851	RECORLEV	
CORRESPONDENCE DATA			
Fax Number:	3102843894		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	4242393744		
Email:	susan.yates@btlaw.com		
Correspondent Name:	Susan Yates		
Address Line 1:	2029 Century Park E Ste 300		
Address Line 4:	Los Angeles, CALIFORNIA 90067		
NAME OF SUBMITTER:	Susan Yates		
SIGNATURE:	/Susan Yates/		
DATE SIGNED:	05/19/2020		
Total Attachments: 7			
source=Avenue - Strongbridge - IPISA - Strongbridge Dublin Limited (5.2020)_ Executed#page1.tif			
source=Avenue - Strongbridge - IPISA - Strongbridge Dublin Limited (5.2020)_ Executed#page2.tif			
source=Avenue - Strongbridge - IPISA - Strongbridge Dublin Limited (5.2020)_ Executed#page3.tif			
source=Avenue - Strongbridge - IPISA - Strongbridge Dublin Limited (5.2020)_ Executed#page4.tif			

OP \$65.00 5237588

source=Avenue - Strongbridge - IPSA - Strongbridge Dublin Limited (5.2020)_ Executed#page5.tif

source=Avenue - Strongbridge - IPSA - Strongbridge Dublin Limited (5.2020)_ Executed#page6.tif

source=Avenue - Strongbridge - IPSA - Strongbridge Dublin Limited (5.2020)_ Executed#page7.tif

PATENT AND TRADEMARK SECURITY AGREEMENT

WHEREAS, STRONGBRIDGE DUBLIN LIMITED, a private limited company incorporated under the laws of Ireland (“*Grantor*”), is party to that certain Security Agreement, dated as of May 19, 2020 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “*Security Agreement*”; capitalized terms used herein without definition shall have the meanings set forth in the Security Agreement), among Grantor, the other Grantors from time to time party thereto and AVENUE VENTURE OPPORTUNITIES FUND, L.P., as administrative agent and collateral agent (in such capacities, together with its successors and assigns, the “*Administrative Agent*”), pursuant to which Grantor has granted in favor of Secured Parties a lien on all of its personal property, including without limitation the patents and patent applications listed on **Schedule A** hereto, and the trademarks and trademark applications listed on **Schedule B** hereto; and

WHEREAS, it is a condition to the advance of the loans and other obligations secured by the Security Agreement, that Grantor execute and deliver, and cause to be filed in the U.S. Patent and Trademark Office, this Patent and Trademark Security Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

As collateral security for the payment in full when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, Grantor hereby pledges and grants to the Administrative Agent for the benefit of the Secured Parties a security interest in all of Grantor’s right, title and interest in, to and under all of the following, as collateral security for the prompt and complete payment and performance when due of all the Secured Obligations (as defined in the Security Agreement):

(i) all patents and patent applications, in each case whether now owned by Grantor or hereafter acquired and whether now existing or hereafter coming into existence, including without limitation those listed on **Schedule A** hereto, including the inventions and improvements described and claimed therein together with the reissues, divisions, continuations, renewals, extensions and continuations in part thereof, all income, royalties, damages and payments now or hereafter due and/or payable with respect thereto, all damages and payments for past or future infringements thereof and rights to sue therefor, and all rights corresponding thereto throughout the world; and

(ii) all of the trademarks, whether now owned or at any time hereafter acquired, of Grantor that are registered with, or for which applications for registration have been filed with, the United States Patent and Trademark Office, including the trademarks listed on **Schedule B** hereto, and all registrations and pending applications associated therewith (excluding any application for registration of a trademark filed on an intent-to-use basis solely to the extent that the grant of a security interest in any such trademark application would materially adversely affect the validity or enforceability of the resulting trademark registration or result in cancellation of such trademark application).

Notwithstanding the foregoing, in the event of any conflict between this Patent and Trademark Security Agreement and the Security Agreement, the Security Agreement shall control.


This Patent and Trademark Security Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; *provided that* Section 5-1401 of the New York General Obligations Law shall apply.

[Signature page to follow]

IN WITNESS WHEREOF, Grantor has caused this Patent and Trademark Security Agreement to be duly executed and delivered as of the day and year first above written.

STRONGBRIDGE DUBLIN LIMITED, as Grantor

By



Name: Stephen J. Long

Title: Authorized Signatory

Date: May 19, 2020

**Schedule A
to Patent and Trademark Security Agreement**

PATENTS AND PATENT APPLICATIONS

COR-003

Title / Owner / Inventor	Country/Number
Methods And Compositions For Treating Diabetes, Metabolic Syndrome And Other Conditions STRONGBRIDGE DUBLIN LIMITED Per Märin	US 9,918,984
	US 10,098,877
	US 10,517,868
	US 16/715,690
Ketoconazole Enantiomer in Humans STRONGBRIDGE DUBLIN LIMITED Timothy Andrew Stewart	US 9,198,906

COR-005

Title / Owner / Inventor	Country/Number
Pharmaceutical Compositions Of Water Soluble Peptides With Poor Solubility In Isotonic Conditions And Methods For Their Use Strongbridge Dublin Limited Michel Afargan	US 10,039,801
	US 10,398,751
	US 16/512,536

KEVEYIS

Case Number	Application No.	Filing Date	Title
STRG0001-201T-US	16/201,410	11/27/2018	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0001-201TC1-US	16/780,057	2/3/2020	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0001-201TD1-US	16/535,704	8/8/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201T-US	16/205,602	11/30/2018	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201TD1-US	16/540,447	8/14/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201TD2-US	16/540,450	8/14/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201TD3-US	16/540,456	8/14/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE

KEVEYIS

Case Number	Application No.	Filing Date	Title
STRG0002-201TD4-US	16/540,461	8/14/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201TD5-US	16/540,464	8/14/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-201TD6-US	16/540,468	8/14/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0003-201T-US	16/253,505	1/22/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0004-201T-US	16/253,515	1/22/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0004-201TC1-US	16/535,692	8/8/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0007-101-US	62/863,125	6/18/2019	DICHLORPHENAMIDE COMPOSITIONS AND METHODS OF USE
STRG0008-101-US	62/908,078	9/30/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0001-401-PC	PCT/US19/63505	11/27/2019	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0002-401-PC	PCT/US19/63507	1/29/2020	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
STRG0004-401-PC	PCT/US20/14250	1/20/2020	METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE

Schedule B
to Patent and Trademark Security Agreement

TRADEMARKS AND TRADEMARK APPLICATIONS

Mark / Owner	Country/Number
STRONGBRIDGE BIOPHARMA STRONGBRIDGE DUBLIN LIMITED	US 5,237,588
RECORLEV STRONGBRIDGE DUBLIN LIMITED	US 5,851,851